Medical Companies

August 15, 2009

ARCA Discovery , Inc.

Filed under: Biotechnology — Tags: — medical products @ 5:25 pm

Industry: Pharmaceuticals, Biotechnology
ARCA Discovery, Inc. is a privately held biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. The Company closed a $15 million Series A financing in February, 2006 led by Atlas Venture, Boulder Ventures and Peqout Capital Management. The Company’s first product is bucindolol, a third generation beta-blocker-vasodilator for advanced heart failure and other indications, that promises to be the first genetically-targeted cardiovascular drug. Bucindolol has extensive Phase III data and a unique Phase III DNA sub-study. Using this sub-study, ARCA’s founding scientists have confirmed genetic polymorphisms that interact with bucindolol’s unique pharmacology to modify patient ( www.arcadiscovery.com )

ARCA Discovery , Inc.
1200 17Th Street Suite 620
Denver, Colorado 80202
USA

Tel: (303) 893-1599
Fax: (303) 825-0883

  • Semafore Pharmaceuticals , Inc.
  • ArQule , Inc.
  • Quark Biotech , Inc.
  • Clontech Laboratories , Inc.
  • Flamel Technologies , S.A.
  • Icagen , Inc.
  • Welichem Biotech Inc.
  • Genome Prairie
  • Incyte Corporation
  • MicroIslet , Inc.
  • Vitro Diagnostics , Inc.
  • Echelon Biosciences Inc.
  • Human BioSystems
  • Erimos Pharmaceuticals LLC
  • Lifeline Technologies Inc
  • Rigel Pharmaceuticals , Inc.
  • Actelion Ltd
  • Novacea Inc.
  • Seattle Genetics , Inc.
  • Mendel Biotechnology , Inc.
  • Medical Companies - Medical Companies Sitemap